Prostate Cancer
UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance.
December 4, 2023
First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level
December 1, 2023
Registrational Phase III CLARIFY Trial in Prostate Cancer Commences
December 1, 2023
Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial.
December 1, 2023
Glucocorticoid receptor (GR) activation is associated with increased cAMP/PKA signaling in castrate-resistant prostate cancer.
December 1, 2023
Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis.
November 30, 2023
Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence.
November 30, 2023
Actigraphy-derived measures of sleep and risk of prostate cancer in the UK Biobank.
November 30, 2023
Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer.
November 30, 2023
Clarity's Theranostic Prostate Cancer Trial Progresses at the Highest Dose Level Cohort
November 29, 2023